Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.74 USD +7.03% Intraday chart for Athira Pharma, Inc. +8.73% +12.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis CI
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook CI
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer CI
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease CI
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease CI
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Athira Says Preclinical Results Back Therapeutic Potential of ATH-1105 in ALS; Shares Rise After Hours MT
JMP Securities Adjusts Athira Pharma Price Target to $19 From $20, Maintains Market Outperform Rating MT
Athira Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Business Officer CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer CI
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Comp Value Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Completeness Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2500 Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Value Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Value Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Value Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Dynamic Index CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2500 Value Index CI
Transcript : Athira Pharma, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 08:00 AM
Chart Athira Pharma, Inc.
More charts
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.56 USD
Average target price
7.417 USD
Spread / Average Target
+189.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Athira Pharma, Inc. - Nasdaq
  4. News Athira Pharma, Inc.
  5. Sector Update: Health Care Stocks Decline Premarket Wednesday